

Tabel 4. Medicamenten waarvan met een matige bewijskracht is gerapporteerd dat zij xerostomie, hypofunctie van de speekselklieren (SGH) of sialorrhoea kunnen veroorzaken.

Opmerkingen:

- NE = norepinefrine; 5-HT = 5-hydroxytryptamine (serotonine); GABA = gamma-aminobutyric acid; ACE = angiotensine-converting enzyme.

- * = niet vermeld in het Farmacotherapeutisch Kompas.

- De eigenschappen van de diverse medicamenten die staan opgesomd in rij 3 van tabel 3 werden vooral ontleend aan het studieboek *The Pharmacological Basis of Therapeutics* (zie referentienr. 73).

Medicament	ATC-code	Mechanisme en aangrijpingspunt	Aantal citaties voor:				Aantal bronnen per niveau van bewijskracht				Total aantal publicaties	Referentie(s)
			Monddroogheid	Xerostomie	SGH	Sialorrhoea	A2	B2	A3	B3		
Amisulpride <i>Atypisch antipsychoticum</i>	N05AL05	Antagonist van dopamine & 5-HT	1	0	0	0	1	0	0	1	2	1, 2 (2 is een dieronderzoek)
Asenapine* <i>Atypisch antipsychoticum</i>	N05AH05	Antagonist van dopamine, 5-HT, histamine (H1) & $\alpha(1,2)$ adrenerge receptoren	2	0	0	0	0	1	0	1	2	3, 4
Atenolol <i>Antihypertensivum/ Anti- arrhythmisch</i>	C07AB03	β 1-adrenerge antagonist	1	0	0	0	0	1	0	0	1	5
Azelastine <i>Anti-allergisch</i>	R01AC03,	Histamine (H1) antagonist	1	0	0	0	0	1	0	0	1	6
Cetirizine <i>Anti-allergisch</i>	R06AE07	Histamine (H1) antagonist	2	0	0	0	0	1	0	1	2	6,7
Clobazam <i>Anxiolyticum/ Anticonvulsant</i>	N05BA09	Benzodiazepine - versterkt het effect van GABA effect op zijn receptoren	0	0	0	1	0	1	0	0	1	8
Darifenacine <i>Urologisch - vermindert de activiteit van de blaas</i>	G04BD10	Antimuscarinerg	5	1	0	0	1	2	0	3	6	9-14
Desipramine <i>Antidepressivum</i>	N06AA01	NE-heropnameremmer	2	0	0	0	1	1	0	0	2	15, 16 (16 is een dieronderzoek)
Desloratadine <i>Anti-allergisch/ Antipruritisch</i>	R06AX27	Histamine (H1)-antagonist, antimuscarinerg	2	0	0	0	0	1	0	1	2	17, 18
Desvenlafaxine <i>Antidepressivum</i>	N06AX23	5-HT & NE heropnameremmer	5	0	0	0	0	3	0	2	5	19-23
Dexfenfluramine <i>Eetlust onderdrukker</i>	A08AA04	Zorgt ervoor dat 5-HT vrijkomt	2	0	0	0	0	1	0	1	2	24, 25
Dexmedevanmidine* <i>Hypnoticum sedativum</i>	N05CM18	α 2-adrenerge agonist	1	0	0	0	0	1	0	0	1	26
Didanosine <i>Antiviraal (HIV-1 therapie)</i>	J05AF02	Nucleoside analog, reverse transcriptaseremmer	1	0	0	0	0	1	0	0	1	27

Medicament	ATC-code	Mechanisme en aangrijpingspunt	Aantal citaties voor:				Aantal bronnen per niveau van bewijskracht				Total aantal publicaties	Referentie(s)
			Monddroogheid		Sialorrhoea		A2	B2	A3	B3		
			Xerostomie	SGH	Sub-jectief	Ob-jectief						
Dihydrocodeïne <i>Opioid-analgeticum</i>	N02AA08	Zwakke agonist voor μ -opioidereceptor	1	0	0	0	0	1	0	0	1	28
Dosulepine <i>Antidepressivum</i>	N06AA16	Niet-selectieve 5-HT/NE heropname-remmer, antimuscarinerg, antihistamine (H1)	1	0	0	0	0	1	0	0	1	29
Doxepine <i>Antidepressivum</i>	N06AA12	Niet-selectieve 5-HT/NE heropname-remmer, antimuscarinerg, antihistamine (H1), α 1-adrenerge receptorantagonist	2	0	0	0	0	1	0	0	1	30
Ebastine <i>Anti-allergisch/ Antipruritus</i>	R06AX22	Histamine (H1) antagonist	2	0	0	0	0	3	0	0	3	31-33
Enalapril <i>Antihypertensivum</i>	C09AA02	Angiotensine-converting enzyme (ACE)-remmer	2	0	1	0	0	1	0	0	1	5
Eszopiclone <i>Hypnoticum sedativum</i>	N05CF04	Versterkt het effect van GABA op zijn receptoren	3	0	0	0	0	1	0	2	3	34-36
Etravirine <i>Antiviraal (HIV-1 therapy)</i>	J05AG04	Non-nucleoside reverse transcriptase-remmer	1	0	0	0	1	0	0	0	1	27
Fentanyl <i>Opioid analgeticum</i>	N01AH01, N02AB03	Sterke μ -opioid receptoragonist	1	0	0	0	0	1	0	0	1	26
Fesoterodine <i>Urologisch - vermindert de activiteit van de blaas</i>	G04BD11	Antimuscarinerg	4	0	0	0	0	3	0	1	4	37-41
Haloperidol <i>Antipsychoticum</i>	N05AD01	Antagonist van dopamine, 5-HT, histamine (H1), muscarinerg & α (1,2) adrenergereceptoren	2	0	1	0	0	2	0	0	2	42, 43
Hyosciamine* <i>Antiperistaltisch/ Spasmolyticum</i>	A03BA03	Antimuscarinerg	1	0	0	0	0	1	0	0	1	44
Isradipine <i>Anti-hypertensivum</i>	C08CA03	Calcium kanaalblokker - arteriële vasodilatoire effecten	1	0	0	0	0	1	0	0	1	5
Lamivudine <i>Antiviraal (HIV, hepatitis B)</i>	J05AF05	Nucleoside analog, reverse transcriptase-remmer	1	0	0	0	1	0	0	0	1	27
Levocetirizine <i>Anti-allergisch</i>	R06AE09	Histamine (H1) receptorantagonist	1	0	0	0	0	1	0	0	1	45
Lisinopril <i>Anti-hypertensivum</i>	C09AA03	Angiotensin-converting enzyme (ACE) remmer	1	0	0	0	0	1	0	0	1	46
Lurasidon <i>Antipsychoticum</i>	N05AE05	5-HT/dopamine antagonist, α 2-adrenerg receptorantagonist, partial 5-HT(7) - agonist	1	0	0	0	0	1	0	0	1	47

Medicament	ATC-code	Mechanisme en aangrijpingspunt	Aantal citaties voor:				Aantal bronnen per niveau van bewijskracht				Total aantal publicaties	Referentie(s)
			Monddroogheid		Sialorrhoea		A2	B2	A3	B3		
			Xerostomie	SGH	Sub-jectief	Ob-jectief						
Maraviroc <i>Antiviraal</i>	J05AX09	Voorkomt dat HIV de cellen binnendringt	1	0	0	0	1	0	0	0	1	27
Methyldopa <i>Antihypertensivum</i>	C02AB01	Valse transmitter; synthese van minder krachtig α -methyl-NE i.p.v. NE	2	0	1	0	0	1	0	1	2	48, 49
Mevanprolol* <i>Antihypertensivum/ Anti-arrhythmicum</i>	C07AB02	β 1-adrenerge receptorantagonist	1	1	0	0	0	1	1	0	2	50, 51
Mexiletine* <i>Anti-arrhythmicum</i>	C01BB02	Natrium kanaalblokker	1	0	0	0	0	1	0	0	1	52
Morfine <i>Opioid analgeticum</i>	N02AA01	Sterke agonist op de μ -receptor	2	0	0	0	0	2	0	0	2	53, 54
Naltrexon <i>Behandeling van alcoholisme</i>	N07BB04	Opioid receptorantagonist	1	0	0	0	0	1	0	0	1	55
Nevirapine <i>Antiviraal (HIV-1)</i>	J05AG01	Non-nucleoside reverse transcriptaserepmer	1	0	0	0	1	0	0	0	1	27
Nicotine <i>Voor stoppen met roken</i>	N07BA01	Agonist van nicotinereceptoren	2	0	0	0	0	2	0	0	2	56, 57
Orlistat <i>Tegen overgewicht</i>	A08AB01	remt lipase, die triglyceriden uit het dieet afbreekt	1	0	0	0	0	1	0	0	1	58
Pregabalin <i>Anticonvulsivum bij non-GABA-erinerge mechanismen</i>	N03AX16	Vermindert het vrijkomen van transmitter	3	0	0	0	0	1	0	2	3	59-61
Raltegravir <i>Antiviraal (HIV-1)</i>	J05AX08	Voorkomt het inbouwen van virus-DNA in de chromosomen van de gastheer	1	0	0	0	1	0	0	0	1	27
Saquinavir <i>Antiviraal</i>	J05AE01	HIV proteaseremmer	1	0	0	0	1	0	0	0	1	27
Sertindol <i>Antipsychoticum</i>	N05AE03	Antagonist van dopamine, 5-HT and α 1-adrenergereceptoren	2	0	0	0	0	1	0	1	2	62, 63
Natriumvalproaat <i>Anticonvulsivum</i>	N03AG01	Vermindert de prikkelgevoeligheid van zenuwen door het binnendringen van natrium te remmen	1	0	0	0	0	1	0	0	1	64
Tapentadol <i>Opioid analgeticum</i>	N02AX06	Zwakke μ -opioïd antagonist, en neuronale NE-heropnameremmer	1	0	0	0	0	1	0	0	1	65

Medicament	ATC-code	Mechanisme en aangrijpingspunt	Aantal citaties voor:				Aantal bronnen per niveau van bewijskracht				Total aantal publicaties	Referentie(s)
			Monddroogheid		Sialorrhoea		A2	B2	A3	B3		
			Xerostomie	SGH	Sub-jectief	Ob-jectief						
Terazosine <i>Urologisch - vermindert de obstructie van de urineweg/ antihypertensivum</i>	G04CA03	α 1-adrenerge receptorantagonist	1	0	0	0	0	1	0	0	1	66
Tizanidine <i>Tegen spierspasticiteit</i>	M03BX02	Zorgt voor het vrijkomen van GABA uit ruggenmerg remmery interneuronen, tevens zwakke α 2-adrenerge agonist	2	0	0	0	2	0	0	0	2	67, 68
Vanlvaptan* <i>Diuretisch</i>	C03XA01	Vasopressine V2 receptorantagonist voorkomt de werking van het antidiuretisch (ADH)	1	0	0	0	0	1	0	0	1	69
Tramadol <i>Opioid analgeticum</i>	N02AX02	Zwakke μ -opioïd receptoragonist en NE/5-HT heropnameremmer	1	0	0	0	0	1	0	0	1	53
Tropium* <i>Urologisch- vermindert de activiteit van de blaas</i>	G04BD09	Muscarinerge receptorantagonist	4	0	0	0	0	2	0	2	4	9, 12, 70, 71
Zopiclon <i>Hypnoticum</i>	N05CF01	Non-benzodiazepine - versterkt het effect van GABA	1	0	0	0	0	1	0	0	1	72

Literatuur

- Gareri P, De Fazio P, De Fazio S, Marigliano N, Ferreri Ibbadu G, De Sarro G. Adverse effects of atypical antipsychotics in the elderly: a review. *Drugs Aging*. 2006;23:937-56.
- Godoy T, Riva A, Ekström J. Atypical antipsychotics - effects of amisulpride on salivary secretion and on clozapine-induced sialorrhoea. *Oral Dis*. 2012;18:680-91.
- McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine versus olanzapine in acute mania: A double-blind extension study. *Bipolar Disord*. 2009;11:815-26.
- Timpe EM, Chopra RA. Asenapine: A novel atypical antipsychotic agent for schizophrenia and bipolar I disorder. *J Pharmacy Technol*. 2010;26:352-61.
- Croog SH, Elias MF, Colton T, Baume RM, Leiblum SR, Jenkins CD. Effects of antihypertensive medications on quality of life in elderly hypertensive women. *Am J Hypertens*. 1994;7:329-39.
- Henz BM, Metzner P, O'Keefe E, Zuberbier T. Differential effects of new-generation H1-receptor antagonists in pruritic dermatoses. *Allergy: Eur J Allergy Clin Immunol*. 1998;53:180-3.
- Wellington K, Jarvis B. Cetirizine/pseudoephedrine. *Drugs*. 2001;61:2231-2240; discussion 2241-2232.
- Seo T, Nagata R, Ishitsu T, Murata T, Takaishi C, Hori M, et al. Impact of CYP2C19 polymorphisms on efficacy of clobazam therapy. *Pharmacogenomics*. 2008;9:527-37.
- Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. *Cochrane Database Syst Rev*. 2006;CD003781.
- Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. *Drugs*. 2004;64:1643-56.
- Hegde SS, Eglén RM. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. *Life Sci*. 1999;64:419-28.
- Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. *BJU Int*. 2007;100:987-1006.
- Naruganahalli KS, Sinha S, Hegde LG, Meru AV, Chugh A, Kumar N, et al. Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit model. *Eur J Pharmacol*. 2007;572:207-12.
- But I, Goldstajn MS, Oreskovic S. Comparison of two selective muscarinic receptor antagonists (solifenacin and darifenacin) in women with overactive bladder--the SOLIDAR study. *Coll Antropol*. 2012;36:1347-53.
- Atkinson JH, Slater MA, Capparelli EV, Wallace MS, Zisook S, Abranson I et al. Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial. *J Clin Psychopharmacol*. 2007;27:135-142.
- Koller MM, Cowman RA, Humphreys-Beher MG, Scarpace PJ. An analysis of parotid salivary gland function with desipramine and age in female NIA Fischer 344 rats. *Exp Gerontol*. 2001;36:141-57.
- Aberer W. Desloratadine for the relief of nasal and non-nasal allergy symptoms: An observational study. *Arch Drug Inf*. 2009;2:17-22.
- Wilken JA, Daly AF, Sullivan CL, Kim H. Desloratadine for allergic rhinitis. *Exp Rev Clin Immunol*. 2006;2:209-24.

19. Villaseca P. Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: What needs to be known for practice? *Climacteric*. 2012;15:115-24.
20. Kornstein SG, Clayton AH, Soares CN, Padmanabhan SK, Guico-Pabia CJ. Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. *J Clin Psychopharmacol*. 2010;30:294-299.
21. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. *Curr Med Res Opin*. 2008;24:1877-90.
22. Pae CU. Desvenlafaxine: A new antidepressant or just another one? *Exp Opin Pharmacotherapy*. 2009;10:875-87.
23. Tourian KA, Pitrosky B, Padmanabhan SK, Rosas GR. A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder. *Prim Care Companion CNS Disord*. 2011;13:e1-e10.
24. Swinburn BA, Carmichael HE, Wilson MR. Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors. *Int J Obes Relat Metab Disord*. 1996;20:1033-40.
25. Davis R, Faulds D. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. *Drugs*. 1996;52:696-724.
26. Bajwa SJ, Arora V, Kaur J, Singh A, Parmar SS. Comparative evaluation of dexmedetomidine and fentanyl for epidural analgesia in lower limb orthopedic surgeries. *Saudi J Anaesth*. 2011;5:365-70.
27. Diz Dios P, Scully C. Antiretroviral therapy: effects on orofacial health and health care. *Oral Dis*. 2014;20:136-45.
28. Freye E, Baranowski J, Latasch L. Dose-related effects of controlled release dihydrocodeine on oro-cecal transit and pupillary light reflex. A study in human volunteers. *Arzneimittelforschung*. 2001;51:60-6.
29. Davies EC, Green CF, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: A pilot study. *J Clin Pharm Therap*. 2006;31:335-41.
30. Baker B, Dorian P, Sandor P, Shapiro C, Schell C, Mitchell J et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. *J Clin Psychopharmacol*. 1997;17:15-21.
31. Kalis B. Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. *Drugs*. 1996;52 Suppl 1:30-4.
32. Storms WW. Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US. *Drugs*. 1996;52 Suppl 1:20-5.
33. Pelaez A. Clinical efficacy of ebastine in the treatment and prevention of seasonal allergic rhinitis. *Drugs*. 1996;52 Suppl 1:35-38.
34. Halas CJ. Cost-effectiveness of eszopiclone for the treatment of chronic insomnia. *Expert Rev Pharmacoecon Outcomes Res*. 2007;7:9-17.
35. Monti JM, Pandi-Perumal SR. Eszopiclone: Its use in the treatment of insomnia. *Neuropsychiatr Dis Treat*. 2007;3:441-53.
36. Pollack M, Kinrys G, Krystal A, McCall WV, Roth T, Schaefer K, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. *Arch Gen Psychiatry*. 2008;65:551-62.
37. Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: A head-to-head placebo-controlled trial. *BJU Int*. 2010;105:58-66.
38. McKeage K, Keating GM. Fesoterodine. *Drugs*. 2009;69:731-8.
39. Tzefos M, Dolder C, Olin JL. Fesoterodine for the treatment of overactive bladder. *Ann Pharmacotherapy*. 2009;43:1992-2000.
40. Kay GG, Maruff P, Scholfield D, Malhotra B, Whelan L, Darekar A. Evaluation of cognitive function in healthy older subjects treated with fesoterodine. *Postgrad Med*. 2012;124:7-15.
41. Yamaguchi O, Nishizawa O, Takeda M, Yoshida M, Choo MS, Gu Lee J, et al. Efficacy, safety and tolerability of fesoterodine in Asian patients with overactive bladder. *LUTS: Lower Urinary Tract Symptoms*. 2011;3:43-50.
42. Veselinovic T, Schorn H, Vernaleken I, Hiemke C, Zernig G, Gur R, et al. Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers. *Psychopharmacol*. 2011;218:733-48.
43. Fulton B, Goa KL. Olanzapine. A review of its properties and therapeutic efficacy in the management of schizophrenia and related psychoses. *Drugs*. 1997;53:281-98.
44. Bova JG, Jurdi RA, Bennett WF. Antispasmodic drugs to reduce discomfort and colonic spasm during barium enemas: comparison of oral hyoscyamine, i.v. glucagon, and no drug. *AJR Am J Roentgenol*. 1993;161:965-8.
45. Fang SY, Perng DW, Lee JY, Lin DY, Huang CY. An open-label, multicentre study of levocetirizine for the treatment of allergic rhinitis and urticaria in Taiwanese patients. *Chin J Physiol*. 2010;53:199-207.
46. Gerc V, Begović B, Vehabović M, Voronkov LG, Vataman E, Musić L, et al. Fixed combination lisinopril plus hydro-chlorothiazide in the treatment of essential arterial hypertension: an opened, multi-centre, prospective clinical trial. *Bosn J Basic Med Sci*. 2007;7:377-82.
47. McEvoy JP, Citrome L, Hernandez D, Cucchiari J, Hsu J, Pikalov A, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: A randomized, 6-week, open-label study. *J Clin Psychiatry*. 2013;74:170-9.
48. Webster J, Koch HF. Aspects of tolerability of centrally acting antihypertensive drugs. *J Cardiovasc Pharmacol*. 1996;27: Suppl 3, S49-S54.
49. van Zwieten PA. Centrally acting antihypertensives: a renaissance of interest. Mechanisms and haemodynamics. *J Hypertens Suppl*. 1997;15:S3-8.
50. Narhi TO, Meurman JH, Ainamo A. Xerostomia and hyposalivation: causes, consequences and treatment in the elderly. *Drugs Aging*. 1999;15:103-16.
51. Aneja P, Srinivas A, Biswas AD. Comparative clinical study of the efficacy and safety of a S-metoprolol ER tablet versus a racemate metoprolol ER tablet in patients with chronic stable angina. *Int J Clin Pharmacol Ther*. 2007;45:253-8.
52. Momo K, Homma M, Osaka Y, Inomata S, Tanaka M, Kohda Y. Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. *J Clin Pharmacol*. 2010;50:331-7.
53. Vickers MD, Paravicini D. Comparison of tramadol with morphine for post-operative pain following abdominal surgery. *Eur J Anaesthesiol*. 1995;12:265-71.
54. Zacny JP, Lichtor JL, Flemming D, Coalson DW, Thompson WK. A dose-response analysis of the subjective, psychomotor and physiological effects of intravenous morphine in healthy volunteers. *J Pharmacol Exp Ther*. 1994;268:1-9.
55. Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. *Biol Psychiatry*. 2001;49:914-21.
56. Ossip DJ, Abrams SM, Mahoney MC, Sall D, Cummings KM. Adverse effects with use of nicotine replacement therapy among quitline clients. *Nicotine Tob Res*. 2009;11:408-17.
57. Polosa R, Caponnetto P, Morjaria JB, Papale G, Campagna D, Russo C. Effect of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. *BMC Public Health*. 2011;11:786.
58. Kaya A, Aydin N, Topsever P, Filiz M, Oztürk A, Dağar A, et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. *Biomed Pharmacother*. 2004;58:582-7.

59. Bull E. Drug review - Pregabalin. *Drugs in Context*. 2006;2:65-77.
60. Semel D, Murphy TK, Zlateva G, Cheung R, Emir B. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. *BMC Fam Pract*. 2010;11:85.
61. Vinik A. Clinical Review: Use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. *J Clin Endocrinol Metab*. 2005;90:4936-45.
62. Murdoch D, Keating GM. Sertindole: A review of its use in schizophrenia. *CNS Drugs*. 2006;20:233-55.
63. Karamatskos E, Lambert M, Mulert C, Naber D. Drug safety and efficacy evaluation of sertindole for schizophrenia. *Expert Opin Drug Saf*. 2012;11:1047-62.
64. Kumar A, Gupta M, Jiloha RC, Tekur U. Efficacy of olanzapine and sodium valproate given alone or as add-on therapy in acute mania. A comparative study. *Methods Find Exp Clin Pharmacol*. 2010;32:319-24.
65. Steigerwald I, Muller M, Davies A, Samper D, Sabatowski R, Baron R, et al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: Results of an open-label, phase 3b study. *Curr Med Res Opin*. 2012;28:911-36.
66. Lee E, Lee C. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. *Br J Urol*. 1997;80:606-11.
67. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. *J Pain Symptom Manage*. 2004;28:140-75.
68. Semenchuk MR, Sherman S. Effectiveness of tizanidine in neuropathic pain: an open-label study. *J Pain*. 2000;1:285-92.
69. Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec FS, et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. *Eur J Endocrinol*. 2011;164:725-32.
70. Garely AD, Burrows LJ. Current pharmacotherapeutic strategies for overactive bladder. *Exp Opin Pharmacother*. 2002;3:827-33.
71. MacDiarmid SA, Anderson RU, Armstrong RB, Dmochowski RR. Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies. *J Urol*. 2005;174(4 Pt 1):1301-5; discussion 1305.
72. Delahaye C, Ferrand B, Pieddeloup C, Musch B. Post marketing surveillance of zopiclone: interim analysis on the first 10,000 cases in a clinical study in general practice. *Int Clin Psychopharmacol*. 1990;5(Suppl 2):131-8.
73. Brunton LL. Goodman & Gilman's *The pharmacological basis of therapeutics*. 12th ed. McGraw-Hill Medical, New York, 2011.